Holy Stone Healthcare Co., Ltd. attended 2019 BIO International Convention in Philadelphia, USA on June 3-6.
Holy Stone Healthcare participates in the Atlanta 2019 AACR Annual Meeting (2019/3/29-4/3) poster presentation.
Holy Stone Healthcare Co., Ltd.‘s new drug for colorectal cancer, CA102N, has received from US FDA the IND approval for conducting phase I clinical trial.
Holy Stone Healthcare Co., Ltd. attended 2018 BIO International Convention in Boston, USA on June 4-7.
Holy Stone Healthcare participates in the Chicago 2018 AACR Annual Meeting (2018/4/14-4/18) poster presentation. Dr. Eskouhie Tchaparian will promote the company’s new drug, CA102N, targeting colorectal cancer.
MediWound Ltd. (Nasdaq: MDWD) has signed an agreement with Holy Stone Healthcare Co., Ltd. on October 16, 2017, granting Holy Stone Healthcare the exclusive distribution rights of NexoBrid® in Taiwan.
Holy Stone Healthcare Co., Ltd., together with representatives of MDT Int’l S.A., attended 2017 BIO International Convention in San Diego, USA. on June 19-22.
A research report of IBD98-M for inflammatory bowel disease from Holy Stone Healthcare, is published on 《Molecules》
A pre-clinical (in-vivo & in-vitro) study report from Holy Stone Healthcare's novel targeting anti-cancer drug in colorectal cancer, CA102N, is published on《Nanomedicine》, volume 2017:12 on March 27, 2017.
Dr. Eskouhie Tchaparian, from our Preclinical & Development Division, participated in the AACR Annual Meeting 2017 on April 1 - 5, 2017 at Walter E. Washington Convention Center, Washington, D.C., USA.
Holy Stone Healthcare, together with representatives of Holy Stone Biotech & MDT Int’l, will be exhibiting at 2016 BIO International Convention in USA. The event will be held from June 7th – 9th at Moscone Center, San Francisco.